Search

Your search keyword '"Zeiher, Andreas"' showing total 2,192 results

Search Constraints

Start Over You searched for: Author "Zeiher, Andreas" Remove constraint Author: "Zeiher, Andreas"
2,192 results on '"Zeiher, Andreas"'

Search Results

1. Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation

2. DNMT3A clonal hematopoiesis-driver mutations induce cardiac fibrosis by paracrine activation of fibroblasts

4. Triglyceride Levels, Alirocumab Treatment, and Cardiovascular Outcomes After an Acute Coronary Syndrome

5. Initial therapeutic anticoagulation with rivaroxaban compared to prophylactic therapy with heparins in moderate to severe COVID-19: results of the COVID-PREVENT randomized controlled trial

7. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.

9. Appraisal of Randomized Sham-Controlled Trial Data on Renal Denervation for the Management of Hypertension

12. Lipoprotein(a) and the Effect of Alirocumab on Revascularization After Acute Coronary Syndrome

14. Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial

15. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome

17. Long-term cardiac pathology in individuals with mild initial COVID-19 illness

21. Abstract 13567: Comparison of Change in Lipoprotein(a) Mass and Molar Concentrations by Alirocumab and Risk of Subsequent Cardiovascular Events in ODYSSEY OUTCOMES

23. Abstract 12226: Aging Impairs the Neuro-Vascular Interface in the Heart

24. Percutaneous repair of moderate‐to‐severe or severe functional mitral regurgitation in patients with symptomatic heart failure: Baseline characteristics of patients in the RESHAPE‐HF2 trial and comparison to COAPT and MITRA‐FR trials

25. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.

30. A human cell atlas of the pressure-induced hypertrophic heart

32. Manual der Arbeitsgruppe Interventionelle Kardiologie (AGIK) der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e.V. (DGK): Teil 2: „Durchführung der perkutanen Koronarintervention“

33. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

34. Safety Of The Pcsk9 Inhibitor Alirocumab: insights From 47,296 Patient-Years Of Observation

35. Comparison of Change in Lipoprotein(a) Mass and Molar Concentrations by Alirocumab and Risk of Subsequent Cardiovascular Events in ODYSSEY OUTCOMES

36. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

38. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

39. Additive contribution of microRNA-34a/b/c to human arterial ageing and atherosclerosis

40. Global position paper on cardiovascular regenerative medicine

41. Manual der Arbeitsgruppe Interventionelle Kardiologie (AGIK) der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e. V. (DGK): Teil 1: „Durchführung der diagnostischen Herzkatheteruntersuchung“

48. Type 1 Myocardial Infarction in Patients With Acute Ischemic Stroke.

49. Transcatheter Versus Rapid-Deployment Aortic Valve Replacement: A Propensity-Matched Analysis From the German Aortic Valve Registry

Catalog

Books, media, physical & digital resources